Last reviewed · How we verify
sufentanil-ropivacaine combination
The sufentanil-ropivacaine combination, marketed by Peking University First Hospital, holds a unique position in the pain management market. A key strength is the drug's patent protection, which extends to 2028, providing a significant barrier to generic competition. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | sufentanil-ropivacaine combination |
|---|---|
| Also known as | epidural analgesia using the sufentanil-ropivacaine combination |
| Sponsor | Peking University First Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection (NA)
- Comparing the QoR of PECS Block and GA in Breast-conserving Surgery With Sentinel Lymph Node Biopsy (NA)
- Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia (PHASE4)
- Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery (PHASE4)
- Sacral Canal Block for Hip Replacement the Efficacy and Safety of Controlled Intraoperative Hypotension (NA)
- Effects of Ropivacaine Concentrations on Prolonged Labor Analgesia (NA)
- Peripheral Nerve Blocks vs Selective Spinal Anesthesia in Patients With Femur Fracture (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: